{"id":"https://openalex.org/W4394328512","doi":"https://doi.org/10.6084/m9.figshare.24822063","title":"Supplementary Material for: Pure red cell aplasia induced by atezolizumab in a patient with small cell lung cancer successfully treated with steroid therapy: a case report","display_name":"Supplementary Material for: Pure red cell aplasia induced by atezolizumab in a patient with small cell lung cancer successfully treated with steroid therapy: a case report","publication_year":2023,"publication_date":"2023-01-01","ids":{"openalex":"https://openalex.org/W4394328512","doi":"https://doi.org/10.6084/m9.figshare.24822063"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/24822063","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Pure_red_cell_aplasia_induced_by_atezolizumab_in_a_patient_with_small_cell_lung_cancer_successfully_treated_with_steroid_therapy_a_case_report/24822063","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Pure_red_cell_aplasia_induced_by_atezolizumab_in_a_patient_with_small_cell_lung_cancer_successfully_treated_with_steroid_therapy_a_case_report/24822063","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073641330","display_name":"Keita Kawakado","orcid":"https://orcid.org/0000-0003-2281-7778","observed_orcids":["https://orcid.org/0000-0003-2281-7778"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K., Kawakado","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066495888","display_name":"Sadayoshi Ito","orcid":"https://orcid.org/0000-0002-5092-3626","observed_orcids":["https://orcid.org/0000-0002-5092-3626"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S., Ito","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103278237","display_name":"Koji Kono","orcid":"https://orcid.org/0000-0003-0106-2767","observed_orcids":["https://orcid.org/0000-0003-0106-2767"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K., Kono","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Y., Mitarai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Mitarai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"T., Yanagawa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T., Yanagawa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5114173802","display_name":"Masayuki Nagasaki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M., Nagasaki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pure-red-cell-aplasia","display_name":"pure red cell aplasia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":1.0},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.8859999775886536},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9929999709129333},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9710000157356262},{"id":"https://openalex.org/keywords/corticosteroid-therapy","display_name":"corticosteroid therapy","score":0.6399999856948853},{"id":"https://openalex.org/keywords/prednisolone","display_name":"prednisolone","score":0.9879999756813049},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.6259999871253967},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.5630000233650208},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.984000027179718},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.6629999876022339}],"concepts":[{"id":"https://openalex.org/C2777422296","wikidata":"https://www.wikidata.org/wiki/Q751631","display_name":"Pure red cell aplasia","level":3,"score":0.8896536827087402},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8885869979858398},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5551168322563171},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49253448843955994},{"id":"https://openalex.org/C2780902042","wikidata":"https://www.wikidata.org/wiki/Q177911","display_name":"Steroid","level":3,"score":0.43670883774757385},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.4248092472553253},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3866175711154938},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3523804545402527},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35153084993362427},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3296205401420593},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.22795599699020386},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.16629740595817566},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.12200197577476501},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08445733785629272},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.0},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/24822063","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Pure_red_cell_aplasia_induced_by_atezolizumab_in_a_patient_with_small_cell_lung_cancer_successfully_treated_with_steroid_therapy_a_case_report/24822063","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.24822063","doi":"https://doi.org/10.6084/m9.figshare.24822063","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.24822063","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.24822063.v1","doi":"https://doi.org/10.6084/m9.figshare.24822063.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.24822063.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/24822063","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Pure_red_cell_aplasia_induced_by_atezolizumab_in_a_patient_with_small_cell_lung_cancer_successfully_treated_with_steroid_therapy_a_case_report/24822063","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389886753","https://openalex.org/W4413438241","https://openalex.org/W4396523029","https://openalex.org/W4310365407","https://openalex.org/W7077673375","https://openalex.org/W4400311089","https://openalex.org/W3195289499","https://openalex.org/W3131558816","https://openalex.org/W7141581808","https://openalex.org/W1974074731"],"abstract_inverted_index":{"Introduction:":[0],"Combination":[1],"therapy":[2],"of":[3,66,85,125,144,196],"atezolizumab":[4,41,129,145,158],"and":[5,54,91,128,185],"chemotherapy":[6],"has":[7],"become":[8],"the":[9,78,82,97,101,186],"standard":[10],"treatment":[11],"for":[12],"small-cell":[13,115],"lung":[14,116],"cancer.":[15],"Immune-related":[16],"adverse":[17],"events":[18],"(irAEs)":[19],"can":[20],"occur":[21],"during":[22,167],"immune":[23],"checkpoint":[24],"inhibitor":[25],"administration.":[26],"A":[27,71],"few":[28],"reports":[29],"exist":[30],"on":[31],"pure":[32],"red":[33,169],"cell":[34,171],"aplasia":[35],"(PRCA)":[36],"as":[37,198],"an":[38,199],"irAE":[39,200],"after":[40],"treatment.":[42],"PRCA":[43,155,197],"is":[44],"characterized":[45],"by":[46,157],"normocytic-normochromic":[47],"anemia,":[48],"a":[49,55,64,92,108,138,162,168],"marked":[50],"decrease":[51,56],"in":[52,57,100,130],"reticulocytes,":[53],"bone":[58,163],"marrow":[59,164],"erythroblasts.":[60],"Here,":[61],"we":[62,206],"report":[63],"case":[65],"atezolizumab-induced":[67],"PRCA.":[68],"Case":[69],"presentation:":[70],"69-year-old":[72],"male":[73],"patient":[74],"was":[75,112,153,159,174,188],"brought":[76],"to":[77,95,137,191],"emergency":[79],"department":[80],"with":[81,114,132,176],"chief":[83],"complaint":[84],"seizures.":[86],"Multiple":[87],"metastatic":[88],"brain":[89,109],"tumors":[90],"mass":[93],"suspected":[94],"be":[96],"primary":[98],"lesion":[99],"right":[102],"hilar":[103],"region":[104],"were":[105],"observed.":[106,154],"After":[107,141],"biopsy,":[110],"he":[111],"diagnosed":[113,160],"cancer":[117],"(cT1cN0M1c":[118],"cStage":[119],"IVB).":[120],"He":[121],"received":[122],"four":[123],"courses":[124,143],"carboplatin,":[126],"etoposide,":[127],"combination":[131],"whole-brain":[133],"irradiation,":[134],"which":[135],"led":[136],"partial":[139],"response.":[140],"six":[142],"maintenance":[146],"therapy,":[147],"severe":[148],"anemia":[149,183],"(hemoglobin,":[150],"3.4":[151],"g/dL)":[152],"induced":[156],"using":[161],"biopsy":[165],"performed":[166],"blood":[170],"transfusion.":[172],"Treatment":[173],"started":[175],"prednisolone":[177],"25":[178],"mg/day":[179],"(0.5":[180],"mg/kg/day).":[181],"The":[182],"improved,":[184],"dose":[187],"gradually":[189],"reduced":[190],"5":[192],"mg/day.":[193],"Conclusion:":[194],"Reports":[195],"are":[201],"rare":[202],"but":[203],"important;":[204],"hence,":[205],"reported":[207],"this":[208],"case.":[209]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2024-04-08T00:00:00"}